Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423103 | 0.98 | AKR1C3 (0.39) | AKR1C3AKR1C2PTGS2PTGS1NR1H4 | |
| SCHEMBL6427372 | 0.93 | MEN1 (0.36) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL6425459 | 0.91 | TSHR (0.38) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL6424012 | 0.91 | PDE2A (0.35) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL6427479 | 0.91 | MEN1 (0.36) | AKR1C3AKR1C2NR1H4CYP2C9CYP3A4 | |
| SCHEMBL6425475 | 0.90 | L3MBTL1 (0.39) | — | |
| SCHEMBL6424443 | 0.89 | HSD11B1 (0.37) | CYP3A4CYP2D6 | |
| SCHEMBL6424875 | 0.89 | PDE2A (0.35) | AKR1C3AKR1C2NR1H4CYP2C9CYP3A4 | |
| SCHEMBL6426725 | 0.88 | ALDH1A1 (0.37) | — | |
| SCHEMBL6426016 | 0.88 | HSD11B1 (0.38) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.